v3.26.1
Summary of Significant Accounting Policies - Schedule of Reconciliation of the Company's net loss (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Summary of Significant Accounting Policies [Line Items]    
General and administrative expenses $ 13,660 $ 13,659
Research and development expenses    
Total research and development expenses 16,744 51,171
Total operating loss (30,404) (64,830)
Non-operating income 5,200 1,729
Income tax provision 1 1
Net loss (25,205) (63,102)
Operating Segments [Member]    
Summary of Significant Accounting Policies [Line Items]    
General and administrative expenses 13,660 13,659
Research and development expenses    
Total direct research and development expenses 8,661 46,484
Total indirect and unallocated research and development expenses 8,083 4,687
Total research and development expenses 16,744 51,171
Total operating loss (30,404) (64,830)
Non-operating income 5,200 1,729
Income tax provision 1 1
Net loss (25,205) (63,102)
Clinical trial | Operating Segments [Member]    
Research and development expenses    
Total direct research and development expenses 4,727 42,369
Formulation and CMC | Operating Segments [Member]    
Research and development expenses    
Total direct research and development expenses 3,805 2,270
Preclinical | Operating Segments [Member]    
Research and development expenses    
Total direct research and development expenses 129 1,845
Personnel-related | Operating Segments [Member]    
Research and development expenses    
Total indirect and unallocated research and development expenses 5,367 3,689
Consulting and other | Operating Segments [Member]    
Research and development expenses    
Total indirect and unallocated research and development expenses $ 2,716 $ 998